ADVERTISEMENT
Imetelstat Associated With High OS in Patients With R/R MF
Imetelstat was found to be associated with a significantly lower risk of death compared with “best available therapy” (BAT) in patients with intermediate-to-high risk myelofibrosis (MF) who had previously been treated with Janus kinase (JAK) inhibitors.
Researchers used data from patients with MF treated with imetelstat in the MYF2001 trial, and compared that with real-world data (RWD) from a closely-matched cohort.
“Overall survival (OS) was measured from the time of JAK inhibitor discontinuation to death or censored at last follow-up. To improve comparability, propensity score weighting approaches using average treatment effect for overlap population … and stabilized inverse probability treatment weighting (sIPTW) were used for 10 critical baseline covariates,” wrote lead author Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, Florida, and colleagues.
In the treatment arm, 57 patients, including those with MF who had discontinued ruxolitinib due to lack or loss of response, received imetelstat 9.4 mg/kg every 3 weeks. To provide historical context, RWD was collected from a study of 38 patients treated with BAT at Moffitt Cancer Center, the authors wrote.
In all, the OS was 30 versus 12 months (hazard ratio [HR] 0.35; P= 0.0019).
Under sIPTW analysis, the results were similar. Results of sensitivity analyses were consistent with the primary analysis. The median OS of 29.9 months warrant further evaluation of imetelstat in this poor-prognosis patient population, the researchers wrote.
